Research
Evidence reviews of the drugs sold online — semaglutide, tirzepatide, and what the trials behind them actually measured. No secondary summaries: every claim traced to the trial, the label, or the paper of record.
Every published price, lowest first
Ranked on the standing month-to-month rate — the only number that survives contact with month two, and the one sellers advertise least.
Head-to-head comparisons
Two sellers side by side on price, dose disclosure, format and states served — scored on the same rubric.
5 articles
- Safety
Compounded vs Brand-Name GLP-1: What Actually Differs
Compounded semaglutide is not a generic Wegovy. It is a preparation no agency has reviewed for safety, efficacy or quality before it reaches you.
6 min read - Evidence
GLP-1 for Women and Men: What Actually Differs
There is no women's formulation and no men's one. In a real-world cohort that was 77.5% female, outcomes showed no significant difference by sex — but one interaction does differ, and it is worth raising with a prescriber.
6 min read - Safety
GLP-1 Side Effects: What the Trials Recorded
Nausea and diarrhea lead, mostly during dose escalation, mostly mild to moderate — and between 4% and 7% of trial participants stopped because of them.
6 min read - Evidence
Tirzepatide vs Semaglutide: What the Trials Actually Measured
Tirzepatide produced larger average weight loss in its own trial, but the only randomized head-to-head between the two was run in type 2 diabetes at a half-dose of semaglutide.
7 min read - Evidence
What Happens When You Stop Taking a GLP-1
Two randomized withdrawal trials measured it directly: 6.9% regained after stopping semaglutide, 14.0% after stopping tirzepatide.
6 min read